

FIG. 2c





FIG. 2d






FIG. 3b




FIG. 4

140000no mAb 120000 MOPC21 control Ig T cell proliferation (cpm) CQ.C11 mAb 100000 AE.C9 mAb 80000 AE.F8 mAb 60000 40000 20000 0 24.3 219 0 73 IL-2 dose (pM)

FIG. 5




FIG. 6

70 -MOPC21 control Ig 60 % Inhibition of T cell proliferation CP.B8 50 CQ.C11 AE.C9 40 AF.F4 30 20 10 -10-0 0.1 10 100 1 mAb dose (ug/ml)

FIG. 7




FIG. 8









FIG. 9
















11/14








FIG. 15b




FIG. 15c



13/14




FIG. 16

control lg

anti-gc mAbs




FIG. 17